James D. Cavenagh

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Journal: American journal of hematology

Published: February 05, 2026

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

Journal: Leukemia

Published: October 15, 2024

Resolution of dysglycaemia after treatment of monoclonal gammopathy of endocrine significance.

Resolution of dysglycaemia after treatment of monoclonal gammopathy of endocrine significance.

Journal: European journal of endocrinology

Published: April 14, 2023

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Journal: The Lancet. Haematology

Published: July 22, 2022

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

Journal: The New England journal of medicine

Published: January 05, 2022

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.

Journal: Blood advances

Published: September 10, 2021

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.

Journal: Blood advances

Published: June 09, 2021

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.

Journal: British journal of haematology

Published: December 24, 2020

COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.

COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.

Journal: British journal of haematology

Published: November 22, 2020

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 31, 2018

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Journal: BMC cancer

Published: August 22, 2017

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

Journal: Blood

Published: July 26, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026